News and Opinions

MESOBLAST UPDATE ON COVID-19 ARDS TRIAL

MESOBLAST UPDATE ON COVID-19 ARDS TRIAL

Melbourne, Australia; December 18, and New York, USA; December 17, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory...

read more
The Regenerative Medicine Foundation is a non-profit organization, granted tax-exempt status under Section 501(c)(3) of the United States Internal Revenue Code. Contributions are tax-deductible to the extent allowable by law.

Join Our Mailing List